General preparation method of exosome for presenting tumor antigen and highly activating T cells
The low antigen presentation efficiency was solved by preparing tumor-specific nanostimulators with E. coli expressed in IFN-β gene in tumor immunotherapy. and the high cost of individualized treatment, efficient T cell activation and personalized treatment are achieved.
Patent Information
- Application Number
- CN202411158849.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-22
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-08-22
AI Technical Summary
In the existing tumor immunotherapy, the low antigen presentation efficiency, insufficient T cell activation and high cost of individualized treatment.
By removing the E. coli cell walls expressing the IFN-β gene, tumor-specific nanostimulators were prepared and co-incubated with dendritic cells to extract exosomes presenting tumor antigens and highly activate T cells.
It significantly enhances the ability of T cells to recognize tumor cells, improves the intensity and durability of the immune response, simplifies the preparation process, reduces costs, is suitable for a variety of tumor types, and promotes personalized medical care.
Smart Images

Figure CN119040262A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a general preparation method of exosomes that present tumor antigens and highly activate T cells, belonging to the technical field of biomedicine and immunotherapy. Background Art
[0002] Dendritic cells (DCs), as crucial antigen-presenting cells in the body's immune system, play a core role in initiating and regulating immune responses. Especially in the field of tumor immunotherapy, the functions of DCs have been further explored and utilized, among which dendritic cell derived exosomes (DEx) as a new type of immunotherapy carrier have shown great potential and significance. Specifically, exosomes are nanoscale lipid bilayer vesicles secreted by cells. They carry a variety of biologically active molecules of parent cells, including proteins, RNA and DNA fragments, which can mediate intercellular communication and material exchange. Dex is particularly rich in MHC complexes, co-stimulatory molecules and tumor-associated antigen information. These characteristics make it a natural "immune education tool". In tumor immunotherapy, the application of DEx is mainly reflected in the following aspects:
[0003] In terms of antigen presentation, tumor antigens carried by DEx can be directly presented to T lymphocytes, activating specific T cells, especially CD8 + Cytotoxic T cells, prompting them to recognize and kill tumor cells with the same antigen markers to achieve precise strikes; in terms of breaking immune tolerance, the tumor microenvironment often induces an immunosuppressive state, which limits the function of T cells. DEx can reverse this state and reactivate the immune response at the tumor site by carrying immune activation signals such as cytokines and co-stimulatory molecules; in terms of establishing immune memory, DEx not only promotes immediate anti-tumor immune response, but also helps to form long-term immune memory and prevent tumor recurrence. By simulating the natural immune process, it promotes the generation of memory T cells and provides continuous protection for patients; in terms of safety and convenience, compared with traditional DC cell therapy, the use of DEx as a treatment method is safer. Exosomes avoid the risks of direct cell transfer, and the preparation process is more standardized, which is convenient for quality control and large-scale production, increasing the feasibility and popularity of treatment.
[0004] Although DEx has shown great potential in tumor immunotherapy, its clinical application is still in the research stage and faces challenges such as optimal dose determination, payload optimization, and development of personalized treatment strategies. Therefore, it is necessary to continuously explore and improve the preparation, modification, and utilization of DEx in order to maximize its benefits in tumor immunotherapy and provide cancer patients with safer and more effective treatment options. Summary of the invention
[0005] In view of the problems of low antigen presentation efficiency, insufficient T cell activation and high cost of individualized treatment in existing tumor immunotherapy methods, the purpose of the present invention is to provide a general method for preparing exosomes that present tumor antigens and highly activate T cells. First, a tumor-specific nanostimulator that stimulates dendritic cells is prepared, and then it is co-incubated with dendritic cells to allow dendritic cells to secrete exosomes that can present tumor antigens and highly activate T cells. Compared with other engineered exosomes, the method of the present invention is simpler and can reduce costs, so as to achieve the above-mentioned purpose and function.
[0006] To achieve the above objectives, the technical solution of the present invention is as follows.
[0007] A general method for preparing exosomes that present tumor antigens and highly activate T cells, the method steps comprising:
[0008] (1) removing the cell wall of Escherichia coli expressing the IFN-β gene to obtain protoplasts, mixing the protoplasts with tumor antigens, collecting the supernatant containing nanoprotoplasts with a particle size of 100 to 900 nm, and preparing a tumor-specific nanostimulator;
[0009] (2) Tumor-specific nanostimulators are added to complete culture medium, dendritic cells are incubated, and exosomes are extracted to obtain exosomes that present tumor antigens and highly activate T cells.
[0010] Preferably, in step (1), when preparing the tumor-specific nanostimulator: the engineered Escherichia coli strain carrying the IFN-β gene is inoculated into an M9 medium containing 0.05-0.2 mM isopropyl-β-D-thiogalactoside for culture, and the Escherichia coli precipitate is collected by centrifugation; the Escherichia coli precipitate is added to a lysozyme bacteria wall-breaking buffer, incubated and the Escherichia coli cell wall is removed, and the protoplasts are collected by centrifugation; the protoplasts and tumor antigens are mixed in a Tris-HCl buffer at a total protein concentration ratio of 2:1-6:1, ultrasonicated at 30-40 W ultrasonic power for 10-30 minutes, centrifuged to remove large particles, and the supernatant containing nanoprotoplasts with a particle size of 100-900 nm is collected to obtain the tumor-specific nanostimulator.
[0011] Preferably, in step (1), the culture conditions are: shaking at 180-220 rpm at 37°C for 15-20 hours.
[0012] Preferably, in step (1), the composition of the lysozyme bacteria cell wall breaking buffer is: 50mM Tris-HCl, 5mM EDTA-2Na, 4mg / ml lysozyme, 0.9wt% glucose; the pH of the buffer is 8.0.
[0013] Preferably, in step (1), the concentration of Tris-HCl buffer is 50 mM and the pH is 8.0.
[0014] Preferably, in step (1), the incubation conditions are: incubation at 37°C for 0.5 to 2 hours; and removal of the E. coli cell wall is performed at 4°C.
[0015] Preferably, in step (1), the conditions for collecting the E. coli precipitate and the protoplasts by centrifugation are: centrifugation at 3000-6000g for 10-30 minutes at 4°C.
[0016] Preferably, in step (1), the conditions for removing large particles by centrifugation are: centrifugation at 100-200 g for 5-10 minutes at 4°C.
[0017] Preferably, in step (2), when extracting exosomes that present tumor antigens and highly activate T cells: the tumor-specific nanostimulator is configured with complete culture medium to a concentration of 40 to 100 μg / ml, dendritic cells are incubated for 24 to 48 hours, and the cell culture supernatant is collected; then centrifuged at 1000 to 1500 rpm for 3 to 5 minutes to remove suspended cells or other large particles, the supernatant is collected, and the exosomes are extracted using a total exosome separation kit, filtered, and exosomes that present tumor antigens and highly activate T cells are obtained.
[0018] Preferably, in step (2), the tumor-specific nanostimulator is prepared with complete culture medium at a concentration of 50 to 80 μg / ml.
[0019] Preferably, in step (2), 0.22 μm water microporous membrane filtration is used.
[0020] An exosome that presents tumor antigens and highly activates T cells is prepared by the above method.
[0021] Beneficial Effects
[0022] The present invention provides a universal preparation method for exosomes that present tumor antigens and highly activate T cells. After removing the cell wall of Escherichia coli expressing IFN-β, protoplasts are obtained, and the protoplasts are mixed with tumor antigens to ensure the dosage and optimal loading efficiency of the tumor antigen; then ultrasonic treatment and centrifugation are performed to remove large particles, and the supernatant containing nanoprotoplasts with a particle size of 100 to 900 nm is collected to ensure successful uptake by dendritic cells, so that the dendritic cells secrete these exosomes with specific functions.
[0023] The method of the present invention has the following advantages, specifically:
[0024] (1) Enhanced immune recognition: This method can effectively increase the level of tumor-specific antigens expressed on the surface of exosomes, thereby significantly enhancing the ability of T cells to recognize tumor cells. This not only increases the targeting of immunotherapy, but also improves the therapeutic effect.
[0025] (2) Improve T cell activation efficiency: By optimizing the preparation conditions of exosomes, the present invention can promote the interaction between exosomes and T cells, significantly increase the activation rate of T cells, and thus improve the intensity and durability of the immune response. Specifically, mixing protoplasts with tumor antigens under specific conditions can ensure the dosage and optimal loading efficiency of tumor antigens; ultrasonic treatment and centrifugation under specific conditions to remove large particles and collect the supernatant containing nanoprotoplasts with a particle size of 100 to 900 nm can ensure successful uptake by dendritic cells, so that dendritic cells can secrete these exosomes with specific functions.
[0026] (3) Reduce nonspecific activation: Traditional methods may cause nonspecific immune responses when activating T cells. However, the present invention effectively avoids nonspecific activation and reduces side effects during treatment by precisely controlling the composition and structure of exosomes.
[0027] (4) Simplified preparation process: Compared with the existing complex and time-consuming preparation methods, the present invention proposes a simpler and more efficient preparation process, which greatly shortens the production cycle, reduces costs, and is conducive to large-scale production and clinical application.
[0028] (5) Adaptability to various tumor types: Since the preparation method of the present invention is highly versatile, it can be applied to various different types of tumor antigens, which means that it has broad clinical application prospects and can meet the needs of different patients.
[0029] (6) Promoting personalized medicine: Based on antigens extracted from individual tumor cells, the preparation method of the present invention can prepare personalized exosome vaccines, further improving the degree of personalization of treatment and enhancing the efficacy. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 Schematic diagram of the production process of exosomes that present tumor antigens and highly activate T cells in Example 1 of the present invention.
[0031] Figure 2 This is a characterization of some of the physical and chemical properties of the tumor-specific nanostimulator used to stimulate dendritic cells in Example 1 of the present invention.
[0032] Figure 3 This is a characterization of some of the physical and chemical properties of exosomes secreted by dendritic cells after stimulation that present tumor antigens and highly activate T cells in Example 1 of the present invention.
[0033] Figure 4 This is the activation effect of the exosomes secreted in Example 1 of the present invention that present tumor antigens and highly activate T cells on T cells. DETAILED DESCRIPTION
[0034] The present invention is further described in detail below in conjunction with specific examples. Unless otherwise specified, the raw materials and operating techniques involved in the following examples and comparative examples are conventional raw materials and techniques in the prior art.
[0035] like Figure 1 As shown, a general method for preparing exosomes that present tumor antigens and highly activate T cells, the method steps comprising:
[0036] (1) Preparation of tumor-specific nanostimulators: an engineered Escherichia coli strain carrying an IFN-β gene is inoculated into an M9 medium containing 0.05-0.2 mM isopropyl-β-D-thiogalactoside for culture, and the Escherichia coli precipitate is collected by centrifugation; the Escherichia coli precipitate is added to a lysozyme bacterial cell wall breaking buffer, incubated and the Escherichia coli cell wall is removed, and the protoplasts are collected by centrifugation; the protoplasts and tumor antigens are mixed in a Tris-HCl buffer at a total protein concentration ratio of 2:1-6:1, and ultrasonicated at 30-40 W ultrasonic power for 10-30 minutes, and large particles are removed by centrifugation, and the supernatant containing nanoprotoplasts with a particle size of 100-900 nm is collected to prepare the tumor-specific nanostimulator;
[0037] (2) Secretion of exosomes that present tumor antigens and highly activate T cells: The tumor-specific nanostimulator is prepared with complete culture medium at a concentration of 40 to 100 μg / ml, dendritic cells are incubated for 24 to 48 hours, and the cell culture supernatant is collected; then centrifuged at 1000 to 1500 rpm for 3 to 5 minutes to remove suspended cells or other large particles, the supernatant is collected, and the exosomes are extracted using a total exosome isolation kit, filtered, and exosomes that present tumor antigens and highly activate T cells are obtained.
[0038] Example 1
[0039] (1) Preparation of tumor-specific nanostimulators: The engineered E. coli strain carrying the IFN-β gene (PET-22b-IFN-β-His) was inoculated into M9 medium containing 0.1 mM isopropyl-β-D-thiogalactoside and shaken at 200 rpm for 18 hours at 37°C. The E. coli precipitate was collected by centrifugation at 4,500 g for 15 minutes at 4°C. The precipitate was added to 50 mM Tris-HCl (pH 8.0, 5 mM EDTA-2Na, 4 mg / ml lysozyme, 0.9% glucose), incubated at 37°C for 1 hour, incubated at 4°C to remove the bacterial cell wall, and centrifuged at 4,500 g for 15 minutes at 4°C to collect the protoplasts. The protoplasts were mixed with tumor antigens (extracted EG7-OVA tumor cell whole protein) at a total protein concentration ratio of 5:1 in 20 ml Tris-HCl (50 mM, pH 8.0), and sonicated at 35 W for 20 min. The mixture was centrifuged at 150 g for 5 min at 4 ° C to remove large particles, and the supernatant containing nanoprotoplasts was collected.
[0040] (2) Secretion of exosomes that present tumor antigens and highly activate T cells: The above tumor-specific nanostimulator was prepared with complete culture medium to a final concentration of 50 μg / ml, and dendritic cells were incubated for 48 hours, and all cell culture supernatants were collected. Centrifugation was performed at 1000 rpm for 5 minutes to remove suspended cells or other large particles, and all supernatants were collected. Exosomes were extracted using a total exosome isolation kit (brand: Thermo Fisher, catalog number: 4478359), and filtered using a 0.22 μm water-based microporous membrane to obtain exosomes that present tumor antigens and highly activate T cells.
[0041] Figure 2 The particle size and surface potential of the tumor-specific nanostimulator (nano-P-IO group in the figure) obtained in this example are characterized. The results show that the particle size of the nanostimulator is approximately between 600 and 800 nm, and the surface has a negative potential.
[0042] Figure 3 The particle size and surface potential of the exosomes (exo-IO group in the figure) obtained in this example that present tumor antigens and highly activate T cells are characterized. The results show that the particle size of the nanostimulator is approximately between 40 and 50 nm, and the surface has a negative potential.
[0043] Figure 4 The results of the test on the activation effect of exosomes on T cells obtained in this example, which present tumor antigens and highly activate T cells, show that CD4 + and CD8 + T cells (i.e. activated CD4 + and CD8 +T cells) was significantly increased, indicating that this exosome has a direct activation effect on T cells.
[0044] Example 2
[0045] (1) Preparation of tumor-specific nanostimulators: The engineered E. coli strain carrying the IFN-β gene (PET-22b-IFN-β-His) was inoculated into M9 medium containing 0.1 mM isopropyl-β-D-thiogalactoside and shaken at 180 rpm for 20 hours at 37°C. The E. coli precipitate was collected by centrifugation at 3,000 g for 30 minutes at 4°C. The precipitate was added to 50 mM Tris-HCl (pH 8.0, 5 mM EDTA-2Na, 4 mg / ml lysozyme, 0.9% glucose), incubated at 37°C for 0.5 hours, incubated at 4°C to remove the bacterial cell wall, and centrifuged at 3,000 g for 30 minutes at 4°C to collect the protoplasts. The protoplasts were mixed with tumor antigens (extracted EG7-OVA tumor cell whole protein) at a total protein concentration ratio of 6:1 in 20 ml Tris-HCl (50 mM, pH 8.0) and sonicated at 30 W for 30 min. The mixture was centrifuged at 150 g for 5 min at 4 ° C to remove large particles, and the supernatant containing nanoprotoplasts was collected.
[0046] (2) Secretion of exosomes that present tumor antigens and highly activate T cells: The above tumor-specific nanostimulator was prepared with complete culture medium to a final concentration of 40 μg / ml. After incubating dendritic cells for 48 hours, all cell culture supernatants were collected. Centrifugation was performed at 1000 rpm for 5 minutes to remove suspended cells or other large particles, and all supernatants were collected. Exosomes were extracted using a total exosome isolation kit (brand: Thermo Fisher, catalog number: 4478359), and filtered using a 0.22 μm water-based microporous membrane to obtain exosomes that present tumor antigens and highly activate T cells.
[0047] The particle size and surface potential characterization results of the tumor-specific nano-stimulator obtained in this example show that the particle size of the nano-stimulator is approximately between 600 and 800 nm, and the surface has a negative potential.
[0048] The particle size and surface potential characterization results of the exosomes presenting tumor antigens and highly activating T cells obtained in this example show that the particle size of the nanostimulator is approximately between 40 and 50 nm, and the surface has a negative potential.
[0049] The results of the test on the activation effect of the exosomes on T cells obtained in this example, which present tumor antigens and highly activate T cells, showed that CD4 + and CD8 + T cells (i.e. activated CD4 + and CD8+ T cells), indicating that the exosomes have a direct activation effect on T cells.
[0050] Example 3
[0051] (1) Preparation of tumor-specific nanostimulators: The engineered E. coli strain carrying the IFN-β gene (PET-22b-IFN-β-His) was inoculated into M9 medium containing 0.1 mM isopropyl-β-D-thiogalactoside and shaken at 220 rpm for 15 hours at 37°C. The E. coli precipitate was collected by centrifugation at 6000g for 10 minutes at 4°C. The precipitate was added to 50mMTris-HCl (pH8.0, 5mM EDTA-2Na, 4mg / ml lysozyme, 0.9% glucose), incubated at 37°C for 2 hours, incubated at 4°C to remove the bacterial cell wall, and centrifuged at 6000g for 10 minutes at 4°C to collect the protoplasts. The protoplasts were mixed with tumor antigen (extracted EG7-OVA tumor cell whole protein) at a total protein concentration ratio of 2:1 in 20 ml Tris-HCl (50 mM, pH 8.0) and sonicated at 40 W for 10 min. The mixture was centrifuged at 150 g for 10 min at 4 ° C to remove large particles, and the supernatant containing nanoprotoplasts was collected.
[0052] (2) Secretion of exosomes that present tumor antigens and highly activate T cells: The above tumor-specific nanostimulator was prepared with complete culture medium to a final concentration of 100 μg / ml, and dendritic cells were incubated for 24 hours, and all cell culture supernatants were collected. Centrifugation was performed at 1500 rpm for 3 minutes to remove suspended cells or other large particles, and all supernatants were collected. Exosomes were extracted using a total exosome isolation kit (brand: Thermo Fisher, catalog number: 4478359), and filtered using a 0.22 μm water-based microporous membrane to obtain exosomes that present tumor antigens and highly activate T cells.
[0053] The particle size and surface potential characterization results of the tumor-specific nano-stimulator obtained in this example show that the particle size of the nano-stimulator is approximately between 600 and 800 nm, and the surface has a negative potential.
[0054] The particle size and surface potential characterization results of the exosomes presenting tumor antigens and highly activating T cells obtained in this example show that the particle size of the nanostimulator is approximately between 40 and 50 nm, and the surface has a negative potential.
[0055] The results of the test on the activation effect of the exosomes on T cells obtained in this example, which present tumor antigens and highly activate T cells, showed that CD4 + and CD8 + T cells (i.e. activated CD4 +and CD8 + T cells), indicating that the exosomes have a direct activation effect on T cells.
[0056] In summary, the invention includes but is not limited to the above embodiments. Any equivalent substitution or partial improvement made under the spirit and principle of the invention shall be deemed to be within the protection scope of the invention.
Claims
1. A general method for preparing exosomes that present tumor antigens and highly activate T cells. Features: The method steps include: (1) removing the cell wall of Escherichia coli expressing the IFN-β gene to obtain protoplasts, mixing the protoplasts with tumor antigens, collecting the supernatant containing nanoprotoplasts with a particle size of 100 to 900 nm, and preparing a tumor-specific nanostimulator; (2) Tumor-specific nanostimulators are added to complete culture medium, dendritic cells are incubated, and exosomes are extracted to obtain exosomes that present tumor antigens and highly activate T cells.
2. A general method for preparing exosomes that present tumor antigens and highly activate T cells as claimed in claim 1, Features: In step (1), when preparing the tumor-specific nano-stimulator: the engineered Escherichia coli strain carrying the IFN-β gene is inoculated into an M9 culture medium containing 0.05-0.2 mM isopropyl-β-D-thiogalactoside for cultivation, and the Escherichia coli precipitate is collected by centrifugation; the Escherichia coli precipitate is added to a lysozyme bacteria wall-breaking buffer, incubated and the Escherichia coli cell wall is removed, and the protoplasts are collected by centrifugation; the protoplasts and tumor antigens are mixed in a Tris-HCl buffer at a total protein concentration ratio of 2:1-6:1, ultrasonicated at an ultrasonic power of 30-40 W for 10-30 minutes, centrifuged to remove large particles, and the supernatant containing nano-protoplasts with a particle size of 100-900 nm is collected to obtain the tumor-specific nano-stimulator.
3. A general method for preparing exosomes that present tumor antigens and highly activate T cells as claimed in claim 2, Features: In step (1), the culture conditions are: shaking at 180-220 rpm at 37°C for 15-20 hours.
4. A general method for preparing exosomes that present tumor antigens and highly activate T cells as claimed in claim 2, Features: In step (1), the composition of the lysozyme bacteria cell wall breaking buffer is: 50mM Tris-HCl, 5mM EDTA-2Na, 4mg / ml lysozyme, 0.9wt% glucose; the pH of the buffer is 8.
0.
5. A general method for preparing exosomes that present tumor antigens and highly activate T cells as claimed in claim 2, Features: In step (1), the concentration of Tris-HCl buffer is 50 mM and the pH is 8.
0.
6. A general method for preparing exosomes that present tumor antigens and highly activate T cells as claimed in claim 2, Features: In step (1), the incubation conditions are: incubation at 37°C for 0.5 to 2 hours; and removal of the E. coli cell wall is performed at 4°C.
7. A general method for preparing exosomes that present tumor antigens and highly activate T cells as claimed in claim 2, Features: In step (1), the conditions for collecting the E. coli precipitate and the protoplasts by centrifugation are: centrifugation at 3000-6000 g for 10-30 minutes at 4°C; The conditions for centrifugation to remove large particles are: centrifugation at 100-200g for 5-10 minutes at 4°C.
8. A general method for preparing exosomes that present tumor antigens and highly activate T cells as claimed in claim 1, Features: In step (2), when extracting exosomes that present tumor antigens and highly activate T cells: the tumor-specific nanostimulator is configured with complete culture medium to a concentration of 40 to 100 μg / ml, dendritic cells are incubated for 24 to 48 hours, and the cell culture supernatant is collected; then centrifuged at 1000 to 1500 rpm for 3 to 5 minutes to remove suspended cells or other large particles, the supernatant is collected, and the exosomes are extracted using a total exosome isolation kit, filtered, and exosomes that present tumor antigens and highly activate T cells are obtained.
9. A general method for preparing exosomes that present tumor antigens and highly activate T cells as claimed in claim 2, Features: In step (2), the tumor-specific nanostimulator is prepared with complete culture medium to a concentration of 50 to 80 μg / ml; Use 0.22μm water microporous membrane filter.
10. An exosome that presents tumor antigens and highly activates T cells, Features: It is prepared by the method according to any one of claims 1 to 9.
Citation Information
Patent Citations
Methods to treat diseases with protein, peptide, antigen modification and hemopurification
CN109415408A
Nanometer artificial antigen presenting cell, and preparation method and application thereof
CN113041342A
Core / shell structure platform for immunotherapy
CN115845040A
Novel high-immunogenicity tumor whole-cell vaccine as well as preparation and application thereof
CN116672441A
Culture method for activating in-vitro amplification and activation of T cells by utilizing tumor exosomes
CN118360246A
Cited By
Method for preparing cell-derived exosome as well as product and application of cell-derived exosome
CN121518393A
